|
Post by JHam on Jul 16, 2014 14:22:49 GMT
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc. is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries. The biopolymer devices are designed to protect the damaged spinal cord from further secondary injury and promote neuroplasticity, a process where functional recovery can occur through the rerouting of signalling pathways to the spared healthy tissue. The Company’s biopolymer-based devices are surgically implanted or injected into the lesion created during traumatic injury, or the primary injury. The Company’s porous biopolymer scaffold consists of polylactic-co-glycolic acid (PLGA) and-polylysine. The Company focuses to develop an injectable hydrogel designed to counteract the inflammatory environment.
|
|
|
Post by tradeup on Jul 25, 2014 17:19:07 GMT
New 52-week low today at $0.90. If it breaks into the $80's I'm probably going to have to buy some.
|
|
|
Post by hophead on Aug 13, 2014 19:16:45 GMT
Anybody following this? i was in nviv a long time ago but sold out. This thing has been nose diving. keeps breaking new lows. I'm wondering if this would be worth a bottom play at some point. Does anyone have any info on possible catalysts in the near future?
|
|
|
Post by sethd023 on Aug 13, 2014 20:18:41 GMT
I've been wondering the same thing. It seems like it has to bounce at some point, but not sure where the bottom is and how fast it will stage some sort of recovery.
|
|
|
Post by hophead on Aug 13, 2014 20:21:56 GMT
Is this company waiting on approval for trials or waiting to release some sort of trial results? TIA...
|
|
|
Post by sethd023 on Aug 13, 2014 20:50:26 GMT
I took a quick look at this August 7 report by Zacks (https://finance.yahoo.com/news/nviv-financial-business-invivo-therapeutics-193000268.html), and this is what I got out of it in terms of catalysts on the horizon:
"Announcing the start of the pilot study is clearly a positive event for InVivo. It has been over three years since the filing of the first IDE application. The next step for the company is to find and enroll the first patient. This will be an open-label design, so we expect that the company will keep investors in the loop as the three, six, and twelve-month data becomes available from this first patient.
The Neuro-Spinal Scaffold in the HUD population easily looks like a $500 million drug. If that’s the case, InVivo’s stock is certainly very attractive at a market capitalization of only $75 million today ($100 million fully-diluted). We think a valuation inflection may come upon the public release of the three-month safety and initial efficacy data from this pilot study. Unfortunately, it has been four months since the trial opened for enrollment and we are still waiting for the first patient to undergo the surgery.
We are optimistic on the InVivo story, but believe the shares will remain under pressure until the first patient is enrolled, treated, and the data becomes available. We encourage investors to stay tuned for the next update. Rating is 'Neutral' but could quickly be changed with positive momentum in the trial once the first patient is enrolled."
|
|
|
Post by actcfan on Aug 13, 2014 21:35:15 GMT
Bunch of shareholder lawsuits have cropped up, I have not dug into them but something to look at.
|
|
|
Post by hophead on Aug 14, 2014 13:43:42 GMT
Thanks for the replies guys. i think i will stay on the sidelines on this for a while.
|
|
|
Post by davidconrad on Aug 14, 2014 14:20:58 GMT
Here is a link to the Law office that is bringing the suit. You'll see that this seems to be the main area of focus. I'm not sure what this says about the merits of the case. www.howardsmithlaw.com/
|
|
|
Post by lanzapaste on Aug 15, 2014 17:39:52 GMT
My impression is the shareholders lawsuit will ultimately be viewed as frivolous - I'm actually surprised a similar type suit hasn't cropped up from ACTC investors who claim they were lead to believe our PH1 trial was going to be MUCH shorter (1yr approx).
Anyways, NVIV can be had right now for .65 per share (60M market cap). I think this is a good time to open a short term trading position - I'm just about to put my money where my mouth is.
|
|
|
Post by tradeup on Aug 16, 2014 1:00:20 GMT
Bought on the premise of this being oversold. Not at all concerned with this lawsuit press release.
Cost-average currently at $0.72.
|
|
|
Post by rickrick on Aug 16, 2014 2:39:34 GMT
This is at the low from Oct 2011. I'm going to see if it bounces here.
|
|
|
Post by davidconrad on Aug 16, 2014 15:22:11 GMT
So perhaps this is one of those lawsuit situations where suits are brought in hopes of provoking an out of court settlement to prevent the further expense...
|
|
|
Post by Keybridge - Cult Member 003 on Aug 16, 2014 17:44:46 GMT
My impression is the shareholders lawsuit will ultimately be viewed as frivolous - I'm actually surprised a similar type suit hasn't cropped up from ACTC investors who claim they were lead to believe our PH1 trial was going to be MUCH shorter (1yr approx). Anyways, NVIV can be had right now for .65 per share (60M market cap). I think this is a good time to open a short term trading position - I'm just about to put my money where my mouth is. I've always been concerned that someone would take a shot at ACT and file a class action - and I wouldn't be surprised if that threat hasn't already been made directly to management in the past. But, to fall outside of the Safe Harbor protections, the plaintiffs have to show fraud, that the company's management was deliberately misleading investors; and that's very challenging. Also, given that the stock is lightly traded and the market cap had remained relatively fixed except for short periods, I'm not sure someone can find a class action period over which there were sufficient damages to make it worthwhile for law firms to pursue a class action. Although I sold my position in NVIV last year, I do like the underlying technology. My sense is that the management of the company now appears relatively weak. I don't believe the dust has settled, and the company's listing will soon come under review since they're coming close to the period that the stock has traded under $1 for close to a month - the min. price regs are actually applied after 30 consecutive business days. I will buy back in, probably sometime in the early Fall when they get into their Phase I and there's clarity on some of these other issues surrounding the company.
|
|
|
Post by tradeup on Aug 18, 2014 16:00:21 GMT
I don't believe the dust has settled, and the company's listing will soon come under review since they're coming close to the period that the stock has traded under $1 for close to a month - the min. price regs are actually applied after 30 consecutive business days.Was NVIV ever listed on Nasdaq or an exchange other than the OTC?
|
|
|
Post by Keybridge - Cult Member 003 on Aug 18, 2014 18:01:29 GMT
I don't believe the dust has settled, and the company's listing will soon come under review since they're coming close to the period that the stock has traded under $1 for close to a month - the min. price regs are actually applied after 30 consecutive business days.Was NVIV ever listed on Nasdaq or an exchange other than the OTC? Good catch, Trade. Invivo is not listed. Point remains the same that this is a stock to be cautious....obviously, being an OTC stock makes matters even worse as an investor, as opposed to being a trader.
|
|
|
Post by rayden on Sept 10, 2014 20:09:56 GMT
Something's up with NVIV today...no news
|
|
|
Post by JHam on Nov 13, 2014 16:42:22 GMT
This is one that doesn't get much attention here (my fault as I should probably have given it its own board), but congrats to those of you who have been holding this one the past few days. Up over 40%.
|
|
|
Post by Yelk on Jan 6, 2015 5:04:31 GMT
Anyone actively following this into 2015? I was reading that a motor biker who was in an accident with totally destroyed spine can now feel again on results? They are pushing trials forward etc. Vist site and do DD. Opinions buying into this while near all time low?
|
|
|
Post by selluwud on Jan 21, 2015 14:35:05 GMT
3 month update announced today with promising results. Going higher
|
|